
Claims


1. Use of a compound of formula I or a pharmacologically acceptable salt thereof



I

in the manufacture of a medicament for the treatment of a brain cancer selected from a MGMT positive astrocytic brain tumour, a metastatic brain cancer and primary CNS lymphoma.

2. Use of a compound of formula I or a pharmacologically acceptable salt thereof



I

in the manufacture of a medicament for the treatment of MGMT positive glioblastoma multiforme.

3. Use of a compound of formula I or a pharmacologically acceptable salt thereof according to claim 1, wherein the MGMT positive astrocytic brain tumour is selected from a diffuse (WHO grade II) astrocytoma and an anaplastic (WHO grade III) astrocytoma.
4. Use of a compound of formula I or a pharmacologically acceptable salt thereof according to claim 1, wherein the metastatic brain cancer is selected from metastasized breast cancer, metastasized systemic lymphoma, metastasized lung cancer, metastasized melanoma, metastasized sarcoma and metastasized gastro-intestinal cancer.

5. Use of a compound of formula I or a pharmacologically acceptable salt thereof according to claim 1, wherein the metastatic brain cancer is metastasized breast cancer.

6. Use of a compound of formula I or a pharmacologically acceptable salt thereof according to any one of claims 1 to 5, wherein the pharmacologically acceptable salt of the compound of formula I is the hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, sulfamate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, glutamate, glucuronate, glutarate, malate, maleate, succinate, fumarate, tartrate, tosylate, salicylate, lactate, naphthalenesulfonate or acetate

.7. Use of a compound of formula I or a pharmacologically acceptable salt thereof according to any one of claims 1 to 6in the manufacture of a medicament adapted for intravenous administration to a patient in need thereof at a dosage level of from 0.1 mg/kg to 70 mg/kg body weight patient.

8. Use of a compound of formula I or a pharmacologically acceptable salt thereof according to claim 7 in the manufacture of a medicament adapted for intravenous administration to the patient in need thereof at a dosage level of from 0.5 mg/kg to 50 mg/kg body weight patient.

9. Use of a compound of formula I or a pharmacologically acceptable salt thereof according to claim 7 or claim 8 in the manufacture of a medicament adapted for intravenous administration to the patient in need thereof on days 1, 8 and 15 of a treatment cycle, on days 1 and 8 of a treatment cycle or day 1 only of a treatment cycle.

10. Use of a compound of formula I or a pharmacologically acceptable salt thereof in the manufacture of a medicament for use in the treatment of a brain cancer according to any one of claims 1 to 9, wherein the patient in need thereof is given radiotherapy either prior to or after treatment of said brain cancer with said medicament.

11. Use of a compound of formula I or a pharmacologically acceptable salt thereof in the manufacture of a medicament for use in the treatment of a brain cancer according to claim 10, wherein the patient in need thereof is given radiotherapy prior to treatment of said brain cancer with said medicament.

12. Use of a compound of formula I or a pharmacologically acceptable salt thereof in the manufacture of a medicament for use in the treatment of a brain cancer according to any one of claims 1 to 9, wherein the patient in need thereof is

treated with a compound of formula I or a pharmacologically acceptable salt thereof and radiotherapy.

13. Use of compound of formula I or a pharmacologically acceptable salt thereof according to any one of claims 10 to 12, wherein the radiotherapy treatment is given at a dose of 1 to 5 Gy over 5 consecutive days, and preferably 2 Gy over 5 consecutive days.

14. Use of compound of formula I or a pharmacologically acceptable salt thereof in the manufacture of a medicament for the treatment of a brain cancer according to any one of claims 1 to 13, wherein the treatment further comprises the administration of a vascular endothelial growth factor (VEGF) inhibitor, and the compound of formula I or a pharmaceutically acceptable salt thereof and the vascular endothelial growth factor (VEGF) inhibitor may be administered concurrently, sequentially or separately.

15. Use of compound of formula I or a pharmacologically acceptable salt thereof according to claim 14, wherein said vascular endothelial growth factor (VEGF) inhibitor is bevacizumab.

16. Use of compound of formula I or a pharmacologically acceptable salt thereof in the manufacture of a medicament for the treatment of a brain cancer according to any one of claims 1 to 13, wherein the treatment further comprises the administration of a poly ADP ribose polymerase (PARP) inhibitor, and the compound of formula I or a pharmaceutically acceptable salt thereof and the poly ADP ribose polymerase (PARP) inhibitor may be administered concurrently, sequentially or separately.

17. Use of a compound of formula I or a pharmacologically acceptable salt thereof according to claim 16, wherein said poly ADP ribose polymerase (PARP) inhibitor is selected from rucaparib, olaparib and veliparib.

18. Use of compound of formula I or a pharmacologically acceptable salt thereof in the manufacture of a medicament for the treatment of a brain cancer according to any one of claims 1 to 13, wherein the treatment further comprises the administration of a PD-1/PDL-1 (immune checkpoint) inhibitor, and the compound of formula I or a pharmaceutically acceptable salt thereof and the PD-1/PDL-1 (immune checkpoint) inhibitor may be administered concurrently, sequentially or separately.

19. Use of a compound of formula I or a pharmacologically acceptable salt thereof according to claim 18, wherein said PD-1/PDL-1 (immune checkpoint) inhibitor is ipilimumab.